P/E společnosti Suda Pharmaceuticals Ltd
Jaká je hodnota metriky P/E společnosti Suda Pharmaceuticals Ltd?
Hodnota metriky P/E společnosti Suda Pharmaceuticals Ltd je N/A
Jaká je definice metriky P/E?
P/E ratio je koeficient daný poměrem ceny akcie a příjmu společnosti na akcii za posledních 12 měsíců.
The price to earnings ratio is the most widely used method for determining whether shares are accurately valued in relation to one another. But the P/E ratio does not in itself indicate whether the share is a bargain. The P/E ratio depends on the market’s perception of the risk and future growth in earnings. A company with a low P/E ratio indicates that the market perceives it as a higher risk or a lower growth or both as compared to a company with a higher price to earnings ratio. The P/E ratio of a listed company’s stock is the result of the collective perception of the market as to how risky the company is and what its earnings growth prospects are in relation to that of other companies. Investors use the P/E ratio to compare their own perception of the risk and growth of a company against the market’s collective perception of the risk and growth as reflected in the current P/E ratio.
P/E společností v sektoru Health Care sektor na ASX ve srovnání se společností Suda Pharmaceuticals Ltd
Čemu se věnuje společnost Suda Pharmaceuticals Ltd?
Suda Pharmaceuticals Ltd engages in the development of drug delivery technology in Australia, India, Europe and Korea. It offers ZolpiMist, an oro-mucosal spray formulation of zolpidem tartrate marketed under the brand name of Ambien or Stilnox, a non-benzodiazepine prescribed for the short-term treatment of insomnia. The company's product pipeline includes Sumatriptan, an oral spray formulation for the treatment of acute migraine; and anagrelide, a platelet lowering agent for use in thrombosis, which is used for the treatment of cancer. Suda Pharmaceuticals Ltd has license and supply agreement with Teva Pharmaceuticals International GmbH and Mitsubishi Tanabe Pharma Singapore for ZolpiMist oral spray; product development, licence, and supply agreement with Cann Pharmaceutical Australia Ltd for the development of novel oral spray of pharmaceutical-grade cannabinoid derivatives for the treatment of drug resistant epilepsy, melanoma, and motion sickness; and feasibility and option agreement with Zelira Therapeutics for the use of cannabinoids for a range of uses, including insomnia, autism, opioid reduction, anxiety, pain, and cancer. The company also has a feasibility study and option agreement with Laboratorios Ordesa, S.L. The company was formerly known as Suda Limited and changed its name to Suda Pharmaceuticals Ltd in November 2017. Suda Pharmaceuticals Ltd was incorporated in 1999 and is headquartered in Osborne Park, Australia.
Firmy s metrikou p/e podobnou společnosti Suda Pharmaceuticals Ltd
- Hodnota metriky P/E společnosti Viva Gold je N/A
- Hodnota metriky P/E společnosti Parazero je N/A
- Hodnota metriky P/E společnosti Orsted A/S Dk 10 je N/A
- Hodnota metriky P/E společnosti Southern Hemisphere Mining je N/A
- Hodnota metriky P/E společnosti Buderim je N/A
- Hodnota metriky P/E společnosti BioVie je N/A
- Hodnota metriky P/E společnosti Suda Pharmaceuticals Ltd je N/A
- Hodnota metriky P/E společnosti GR Silver Mining je N/A
- Hodnota metriky P/E společnosti Calyxt Inc je N/A
- Hodnota metriky P/E společnosti Strip Tinning Plc Ord je N/A
- Hodnota metriky P/E společnosti IBO Technology je N/A
- Hodnota metriky P/E společnosti Luby`s je N/A
- Hodnota metriky P/E společnosti Cranes Software International je N/A